"Immutep CEO Marc Voigt said, “Our IMP761 preclinical study results are very encouraging. We believe that IMP761 represents a new, more targeted therapeutic approach working upstream from currently available immunosuppressive therapies. IMP761 will be an important part of our development efforts, in addition to our lead product candidate, eftilagimod alpha.”
The presentation materials from this event can be accessed via Immutep’s website.
Webcast
Immutep CSO and CMO, Frédéric Triebel and CEO Marc Voigt will discuss the results and the Company’s plans to advance IMP761 into clinical development on a global webcast in the coming weeks. Details of the webcast will be announced separately."
ooooh I like it.
"Immutep CEO Marc Voigt said, “Our IMP761 preclinical study...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.3¢ | $884.2K | 2.836M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34624 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 250082 | 6 |
View Market Depth
| Last trade - 16.10pm 27/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
